Cerus Corporation (CERS) SEC Filings & Earnings Calls

Gross margin pressure from tariffs and FX

“Our gross margin on product sales was 51% during the three months ended June 30, 2026 compared to 55% during the three months ended June 30, 2025. The margin decrease ... driven primarily by foreign exchange rates and the cost of our product inventory.” · word for word

Customer concentration

“The Company had three customers that accounted for more than 10% of the Company's outstanding accounts receivable at both June 30, 2026 and December 31, 2025. These customers cumulatively represented approximately 58 % and 50 % of the Company's outstanding receivables.” · word for word

Red blood cell system development and regulatory uncertainty

“The red blood cell system is currently in development and may never receive any marketing approvals or CE Certificates of Conformity.” · word for word

Dependence on BARDA funding

“A significant portion of the funding for the development of the red blood cell system has come and is expected to continue to come from our BARDA agreements, and if BARDA were to eliminate, reduce or delay ... funding of our agreements, it would have a significant, negative impact on our government contract revenues and cash flows.” · word for word

Gross margin pressure from FX and inflation

“Product gross margin for the second quarter was 51.4% compared to 55.2% in the same period last year. The year-over-year decrease in gross margin was largely driven by a weaker U.S. dollar relative to the Euro and higher product costs driven by inflationary pressures” · word for word

Cash burn: cash decreased from $82.9M to $56.3M since Dec 2025

“At June 30, 2026, the Company had cash, cash equivalents, and short-term investments of $56.3 million, compared to $82.9 million at December 31, 2025” · word for word

Leadership transition may create short-term uncertainty, but structured compensation and defined term mitigate risk.

“CEO transition to Executive Chairman with reduced time commitment; no financial impact disclosed.”

Floating rate debt exposes company to interest rate risk; SOFR floor 1%

“bear interest at a floating rate equal to the sum of the Term SOFR rate (subject to a floor of 1.00%) plus 5.50%” · word for word

Covenants include minimum net revenue requirement, limiting operational flexibility

“must also comply with a financial covenant relating to trailing twelve month minimum net revenue requirements” · word for word

Gross margin pressure from inflation, FX, and tariffs; operating cash flow negative due to working capital build.

“Product gross margin decreased to 52.0% from 58.8%; cash used for operations totaled $3.0 million compared to $0.8 million during the same period of the prior year.”

Customer concentration

“Three customers cumulatively represented approximately 58% of outstanding receivables at March 31, 2026”

Gross margin pressure

“Gross margin on product revenue declined from 58.8% to 52.0% year-over-year”

CEO transition execution risk

“On March 16, 2026, we announced that Mr. Jayaraman will be appointed as our next President and Chief Executive Officer and Mr. Greenman will serve as Executive Chairman of the Board, in each case effective July 1, 2026.” · word for word

Equity dilution from increased share reserve

“the aggregate number of shares of our common stock that may be issued under the Amended and Restated 2024 Plan will not exceed 31,910,323 shares ... which is an increase of 10,000,000 shares” · word for word

Concentrated ownership by large holders

“ARK Investment Management LLC ... 19,207,604 ... 9.6% ... BlackRock, Inc. ... 13,782,396 ... 6.9% ... Baker Bros. Advisors LP ... 10,008,345 ... 5.0%”

CEO transition risk; new CEO's strategic direction may differ.

“Orderly succession with internal candidate; former CEO remains as Executive Chairman.”

Red Blood Cell System Regulatory Failure

“The red blood cell system is currently in development and may never receive any marketing approvals or CE Certificates of Conformity.” · word for word

Customer Concentration

“The American Red Cross represents the largest single portion of the blood collection market in the U.S. and is one of our key customers.” · word for word

Single Source Supplier Dependency

“We rely solely on Fresenius Kabi AG... for the manufacture of disposable kits for the platelet and plasma systems.” · word for word

Clinical Trial Antibody Risk

“If treatment emergent antibody reactions associated with hemolysis are observed, the FDA will require us to place a clinical hold and we will need to investigate the underlying cause.” · word for word

Continued Operating Losses

“We may continue to generate losses and never achieve a profitable level of operations.” · word for word

Gross margin pressure from IFC production costs, trade regulation, inflation, and FX.

“Higher IFC therapeutic production costs, ongoing trade regulation and inflationary pressures, as well as foreign exchange rates contributed to the change in product gross margin percentage.” · word for word

Minimal risk; routine board refreshment.

“No disagreement; director term expiring.”

Preliminary results subject to audit

“Preliminary unaudited results; subject to change”

Import tariffs and inflationary pressure impacting gross margins; higher IFC production costs to meet demand.

“Import tariffs, inflationary pressure, and higher IFC production costs impacted product gross margin.” · word for word

U.S. platelet shortage reduces INTERCEPT adoption urgency

“Given the current shortage of platelets in the U.S., hospitals may not discriminate about which platelet products they receive, which may result in less demand for INTERCEPT-treated products and therefore less urgency for blood centers to adopt or increase INTERCEPT-treated platelets.” · word for word

American Red Cross dependency and inconsistent ordering

“Our ability to achieve and maintain significant market penetration in the U.S. is largely dependent on utilization of INTERCEPT and distribution of INTERCEPT-treated blood components by the American Red Cross.” · word for word

IFC manufacturing partner dependency without minimum commitments

“most of our agreements with blood center manufacturing partners do not contain minimum production requirements. If our blood center manufacturing partners do not produce sufficient quantities of IFC, or at all, our commercialization efforts will be negatively impacted.” · word for word

Red blood cell system regulatory delay and uncertainty

“the red blood cell system is currently in development and may never receive any marketing approvals or CE Certificates of Conformity.” · word for word

German reimbursement may not be attractive enough for full adoption

“the reimbursement awarded to INTERCEPT in Germany may not be considered by German blood centers as attractive enough to implement pathogen reduction or cover the entirety of their blood center platelet collections which may in turn limit the market acceptance in Germany.” · word for word